DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/22971699; http://www.ncbi.nlm.nih.gov/pubmed/23318685
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/22971699; http://www.ncbi.nlm.nih.gov/pubmed/23318685
Peginesatide (trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin. It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. Peginesatide is a synthetic peptide, attached to polyethylene glycol ("PEGylated"). It mimics the structure of erythropoietin, the human glycoprotein which promotes red blood cell development. Peginesatide binds to and activates the human erythropoietin receptor and stimulates erythropoiesis in human red cell precursors in vitro.
Originator
Sources: https://www.sec.gov/Archives/edgar/data/1158223/000110465911068407/a11-31307_1ex99d1.htm
Curator's Comment: # Affymax and Takeda Pharmaceutical Company
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P19235 Gene ID: 2057.0 Gene Symbol: EPOR Target Organism: Homo sapiens (Human) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | OMONTYS Approved UseIndicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. Launch Date2012 |
PubMed
Title | Date | PubMed |
---|---|---|
Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. | 2009 Nov |
|
Detection of peginesatide in equine serum using liquid chromatography-tandem mass spectrometry for doping control purposes. | 2012 |
|
Peginesatide as a new approach for treating anemia of CKD patient: is it like a falling star? | 2013 Jul |
|
Relative safety of peginesatide and epoetin alfa. | 2014 Oct |
|
Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis. | 2015 Jul-Aug |
Patents
Sample Use Guides
Initiate OMONTYS treatment when the hemoglobin level is less than 10 g/dL. The recommended starting dose for the treatment of anemia in patients who are not currently
treated with an ESA is 0.04 mg/kg body weight administered as a single intravenous or subcutaneous injection once monthly.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QB03XA04
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
||
|
LIVERTOX |
746
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
||
|
WHO-ATC |
B03XA04
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
||
|
NDF-RT |
N0000175665
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
||
|
NCI_THESAURUS |
C2139
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB33424
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
66889
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
Peginesatide
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
9304
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
1248798
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID501027898
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
C48422
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
4234
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
JX56W9N61Q
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
Peginesatide
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107866
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
1350810-60-4
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
ALTERNATIVE | |||
|
7447
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
ZZ-98
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
913976-27-9
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
DB08894
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
m11692
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
C556270
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
C514771
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
8181
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY | |||
|
66895
Created by
admin on Sat Dec 16 13:27:14 GMT 2023 , Edited by admin on Sat Dec 16 13:27:14 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)